Mounjaro®
Starting from £179.99/mo
Start journey Learn moreIf you're considering a change to Wegovy, the key facts are these: Wegovy (semaglutide 2.4mg–7.2mg) is a once-weekly injection licensed in the UK for weight management in adults with a BMI of 30 or above, or 27 or above with a weight-related health condition. Switching to it, whether from another medicine or from no treatment at all, always requires a fresh clinical assessment by a prescriber. Wegovy is a prescription-only medicine, and what's right for you depends on your health picture, not just what you've been taking. Our prescribers at nume review every case individually before any treatment is issued.
At your door the next working day.
Free, tracked, plain packaging.
BMI isn't the whole story, but it's where clinicians start. Check yours in ten seconds — nothing is stored, nothing is shared.
Ten seconds. Private — nothing is stored or shared.
Your result updates live in the card alongside.
Your result
Your BMI is
—
which is in the healthy weight range
Start journeyBMI doesn't determine eligibility — only a clinician can assess whether treatment is right for you.
The problem
The nume way
clinician review. Free next working day delivery.
How it works
Tell us about your health, history and goals. Free, online, and confidential — no commitment, no waiting room.
Our team reviews your health the same day — never an algorithm, and approves your treatment there and then if eligible.
Order by 12pm, dispatched same day, delivered free the next working day — the nume Promise.
Picture the situation most people arrive in: you've spent months on a different injectable or oral treatment, the results have plateaued, or the side effects have made each week uncomfortable. Maybe your dose can't go higher on your current medicine, or supply has been patchy. Switching to Wegovy isn't unusual in that context. What matters is doing it in the right order.
A prescriber needs to understand where you are before deciding where you start on Wegovy's schedule. Someone who has been on a high dose of a different GLP-1 will not necessarily begin at 0.25mg; equally, they won't automatically jump to a maintenance dose. The starting point is a clinical decision based on your tolerability history, your current weight and any conditions being managed alongside. That's not bureaucracy, it's the difference between a smooth transition and a fortnight of nausea you didn't need to have.
The semaglutide overview on this site covers how Wegovy works in more detail, including the mechanism behind the appetite reduction that most people notice within the first few weeks on a therapeutic dose.
Wegovy is injected once a week, subcutaneously, into the abdomen, thigh or upper arm, rotating sites. If you're moving from another once-weekly injection, the timing is straightforward in principle: you'd take Wegovy where the next dose of the old medicine would have fallen, subject to your prescriber's specific instruction. If you're moving from a daily oral medicine, the prescriber will advise on the overlap or gap.
One practical thing to know: injection day can be shifted if it stops suiting your week, provided you keep at least four days between doses. There's a separate page on changing your Wegovy injection day if that's relevant to you.
Side effects during a switch can feel more pronounced than when continuing a stable dose. GI symptoms (nausea, loose stools, indigestion) tend to be most noticeable in the first week or two after a dose step, then settle. Staying hydrated matters, and eating smaller, lower-fat meals helps most people through the adjustment. If symptoms are severe or don't ease, contact your prescriber rather than pushing through.
Some people also notice changes they weren't expecting. Taste perception can shift on semaglutide, and some women report changes to their cycle. These aren't universal, but they're worth knowing about before you start.
A common question: can you just move from Ozempic to Wegovy? Ozempic contains the same active ingredient (semaglutide) but it is licensed in the UK for type 2 diabetes, not for weight management. Switching from Ozempic to Wegovy is something prescribers do handle, but it's a formal change of indication and of licence, not just a pen swap. The conversation with your prescriber needs to happen first. If you're currently using Ozempic off-label for weight loss, a move to the licensed weight-management product is genuinely worth discussing.
For anyone thinking about cost as part of the decision, Wegovy pricing in the UK has shifted since Novo Nordisk expanded the dose range, and what you pay at different providers varies more than most people realise. It's worth reading before committing.
When you complete a consultation with us, the prescriber reads your answers the same day, a real clinician, not a decision tree. For transfer patients and those requesting a dose increase, we ask for evidence of your current treatment, and the prescriber makes the call on where you start. Orders placed before noon Monday to Friday are dispatched the same day once approved, and DPD delivers the next working day in plain, unbranded packaging. The whole process (consultation, prescription, delivery) is one transparent price with no subscription attached.
If you're not sure whether switching makes clinical sense for you, the FAQs cover many of the common questions, and our aftercare team is available seven days a week. You can also read about the full Wegovy treatment page or explore other weight-loss treatment options if you're still weighing things up. When you're ready, speak to our prescribers to start a free consultation.
The people
Superintendent Pharmacist (GPhC No. 2217101)
Accountable for the safe running of our registered pharmacy, from every dispensing check to every dispatch.
Clinical Lead (GPhC No. 2231744)
Sets our clinical standards and checks everything we publish against current MHRA guidance.
Independent Prescriber (GPhC No. 2084501)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.
Independent Prescriber (GPhC No. 2083426)
Personally reviews consultations and assesses whether treatment is clinically appropriate, and leads dose adjustments and follow-up checks.